


### REMARKS

With this paper, the specification has been amended to correct the required SEQ ID NO identifiers associated with the listed sequences.

In reviewing the file prior to payment of the issue fee, Applicants have noted that no sequence listing was submitted upon entry into the United States national phase and no Notice to Comply Under 37 C.F.R. 1.821 was issued by the United States Patent Office in conjunction with this application. As a consequence, no sequence listing has been filed for this application. In order to bring the application into compliance with 37 C.F.R. 1.821, Applicants submit herewith a paper sequence listing, a CRF of the sequence listing, and a Statement Under 37 C.F.R. 1.825. Applicants respectfully request that the paper sequence listing be incorporated at the end of the specification. No new matter has been introduced by way of the amendments to the specification or the sequence listing.

Applicants believe that no fee is due in association with this submission. If the Applicants are in error, the Commissioner is herewith authorized to charge any underpayment or credit any overpayment that may occur during the pendency of this application to Deposit Account No. 01-0535.

Respectfully submitted,

  
James E. Butler, Ph.D.  
Registration No. 40,931

AMYLIN PHARMACEUTICALS, INC.  
9360 Towne Centre Drive  
San Diego, CA 92121  
(858) 458-8564